For the first time, Americans exposed to COVID-19 will have access to a prescription pill designed to help prevent the illness from developing after contact with an infected person. The approval marks a new phase in the long-term management of a virus that has largely faded from public attention but continues to cause hospitalizations and deaths across the United States.
Shionogi & Co. announced on June 1 that the U.S. Food and Drug Administration (FDA) approved Xocova (ensitrelvir) for post-exposure prevention of COVID-19 in adults and adolescents age 12 and older who have been exposed to someone infected with the virus.
According to the company, Xocova becomes the first FDA-approved oral medication specifically cleared to reduce the risk of developing COVID-19 after exposure.
The treatment is designed to be simple and fast. Patients take three tablets on the first day followed by one tablet daily for the next four days, creating a five-day regimen intended to begin shortly after exposure.
The approval is based on results from the SCORPIO-PEP clinical trial, which enrolled 2,387 participants who had been exposed to an infected household member. According to trial data, people who received Xocova experienced a 67% reduction in the risk of developing symptomatic COVID-19 compared with those who received a placebo.
The drug works by targeting a key enzyme the coronavirus needs to reproduce. By blocking the virus’s main protease, ensitrelvir interferes with viral replication before the infection becomes established.
Reported side effects in clinical trials included headache, diarrhea, and cough. The medication also carries standard warnings regarding use during pregnancy and other medical considerations that should be discussed with a healthcare provider.
While COVID no longer dominates headlines, the virus remains a significant public health concern.
According to estimates from the Centers for Disease Control and Prevention, the United States recorded between 3.8 million and 12.4 million COVID-19 cases between October 2025 and late May 2026. Those infections were associated with as many as 240,000 hospitalizations and 42,000 deaths during the period.
The approval also highlights an important shift within the pharmaceutical industry.
During the pandemic, companies such as Pfizer and Moderna generated billions of dollars from vaccines and treatments developed during the global emergency. As COVID became endemic and demand for those products declined, revenue from pandemic-era medicines fell sharply.
Shionogi is betting that a preventive treatment aimed at recently exposed individuals can fill a different market niche.
The company estimates that nearly half of people living with an infected household member ultimately contract the virus themselves, creating a potentially significant population that may seek preventive treatment following exposure.
The approval follows a lengthy regulatory process.
After earlier efforts to secure U.S. approval for ensitrelvir as a treatment for active COVID-19 infections faced challenges, the company shifted its focus toward prevention, where clinical trial results proved more successful. The FDA granted approval ahead of its scheduled June 16 decision deadline.
The medicine is already approved in Japan, where it initially received emergency authorization in 2022 before later receiving full approval.
Outside experts say the drug’s value lies in its ability to intervene early.
By slowing viral replication shortly after exposure, the treatment may reduce the likelihood that the virus gains a foothold and progresses into symptomatic illness.
For investors and the pharmaceutical industry, the approval represents a test of whether COVID prevention remains a viable commercial market years after the pandemic emergency ended.
The vaccine boom may be over, but COVID continues to circulate globally. The success of Xocova will depend on whether physicians and patients embrace post-exposure treatment as a routine part of managing the virus, or whether most people continue to rely on vaccination, natural immunity, and time.
Either way, the FDA’s decision opens an entirely new category of COVID prevention in the United States.
This article is general business and healthcare reporting and should not be considered medical advice. Individuals should consult a qualified healthcare professional regarding treatment options.
JBizNews Desk — Health Care
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
